Industry : Medical Instruments & Supplies
Employees : 140
Exchange : NASDAQ
111 Pencader Drive
Newark DE 19702
Fax: (302) 456-6770
Strategic Diagnostics Inc., (Nasdaq: SDIX)
Headquartered in Newark, DE USA, is a biotechnology company dedicated to bringing innovative solutions to analytical testing problems through immunotechnology. SDI is a leading developer and manufacturer of immunoassay-based test kits for both field testing and laboratory use. These products are used extensively for contaminated waste site assessment and remediation, water quality management, food labeling and transgenic crop seed production.
SDI is a major developer and producer of antibodies and immunoreagents for a broad range of applications. The company is applying this extensive technical expertise to the rapidly growing agricultural markets for crop disease management as well as to medical and industrial problems. This technological base, along with strong sales, marketing and manufacturing, positions Strategic Diagnostics Inc. to continue to provide new products and services to effectively solve customers current and future analytical problems.
Strategic Diagnostics Announces New Agreement to Supply Diagnostic Antibody Reagents
Strategic Diagnostics Inc. (NASDAQ:SDIX) today announced that it has signed a new agreement to supply bio-reagents to a large manufacturer of in-vitro diagnostics. The initial term of the agreement is five years. Starting revenues are estimated at $1 million per year and are anticipated to more than double over the term of the agreement. Strategic Diagnostics will begin shipping bio-reagents to the customer in the fourth quarter of 2006.
Strategic Diagnostics Inc. and Broin and Associates, Inc. Announce Development Contract for Application of SDI Bacteriophage Technology in Ethanol Production
NEWARK, Del.--(BUSINESS WIRE)--Aug. 28, 2006--Strategic Diagnostics Inc. (Nasdaq:SDIX) and Broin and Associates, Inc., a division of the Broin Companies, today announced the signing of a contract to develop application(s) based on SDI's patent-pending technology utilizing bacteriophage as selective agents. The application(s) will directly support Broin and Associates proprietary BPX technologies for ethanol production. Terms of the agreement were not disclosed.
Latest Press Release Information
[b]Product News Information